Cutaneous side effects of vemurafenib: a case report and discussion.
Wien Med Wochenschr
; 163(15-16): 376-9, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23824179
In 2011, the FDA approved the drug vemurafenib, a potent kinase inhibitor with specificity for the BRAF V600E mutation, for the treatment of metastatic melanoma. While this drug is otherwise well-tolerated, many patients develop cutaneous toxicities. This report demonstrates multiple cutaneous toxicities in a patient while undergoing treatment with vemurafenib.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Sulfonamidas
/
Verrugas
/
Carcinoma de Células Escamosas
/
Segunda Neoplasia Primária
/
Toxidermias
/
Indóis
/
Melanoma
/
Neoplasias Primárias Múltiplas
Tipo de estudo:
Diagnostic_studies
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article